DPA-714

Phase 1Small molecule

UUniversity of Alabama at Birmingham

DPA-714 is one of 40 small molecule programs targeting Glioma. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

GliomaActive, not recruiting

Carotid Artery DiseaseActive, not recruiting

GliomaPreclinical

Active, not recruiting

Carotid Artery DiseasePhase 1

Active, not recruiting

Competition

Competitive Landscape

394 competitors in Glioma

#DrugCompanyPhaseTrials

Paraplatin

AAvyxa

Phase 3

15 2

Trexall

Alnylam Pharmaceuticals

Phase 3

2 3

Tepadina

Alnylam Pharmaceuticals

Phase 3

1 4

Bicnu

MMelissa K Accordino

Phase 3

7 5

Vepesid

AAvyxa

Phase 3

4 6

Photofrin

PPinnacle Biologics Inc.

Phase 3

2 7

Accutane

CConrado Roberto Hoffmann Filho

Phase 3

1 8

Velban

EEastern Cooperative Oncology Group

Phase 3

1 9

Ifex

BBaxter Healthcare Corporation

Phase 3

1 10

Rayos

RRoxane Laboratories

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Glioma1 trial

Contribution of [18F]DPA-714 PET for Grading and Exploration of the Inflammatory Microenvironment of Glioma.

Withdrawn·CCenter Eugene Marquis·N/A·NCT05672082

Carotid Artery Disease1 trial

Neuroinflammation in Asymptomatic Carotid Artery Disease - Imaging Substudy

Withdrawn·UUniversity of Alabama at Birmingham·Phase 1·NCT05238961

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for DPA-714. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — DPA-714 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for DPA-714. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Alabama at Birmingham company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: UUniversity of Alabama at Birmingham

DPA-714

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Glioma1 trial

Carotid Artery Disease1 trial

References

Drug Info

Quick Facts

Related News